Background Current evidence on the association between the platelet-to-high-density lipoprotein cholesterol ratio (PHR) and blood eosinophil counts (BEOC) is limited in pediatric asthma patients. This study aimed to assess the relationship between PHR and BEOC in this population. Methods Using data from the National Health and Nutrition Examination Survey (NHANES) from 2009 to 2020, we conducted a cross-sectional study of 2178 eligible participants. Multivariable linear regression (continuous and quartile PHR) analyzed the association, adjusted for key covariates. Dose-response was assessed using restricted cubic splines (RCS), and robustness was tested with stratified and sensitivity analyses. Results Among 2178 participants (mean age 12.6 ± 3.9 years; 56.3% male), multivariable linear regression revealed a significant positive correlation between PHR and BEOC (β = 12.34; 95% CI: 6.53 to 18.15; P < 0.001). RCS analysis indicated a linear relationship (P = 0.905 for nonlinearity). Subgroup analyses were stable across most strata, stronger in females. Sensitivity analyses in the stricter asthma cohort confirmed robustness. Conclusions This study reveals a significant, positive association between PHR and BEOC in pediatric asthma patients. PHR may serve as a potential biomarker for pediatric eosinophilic asthma phenotypes, though further prospective studies are needed to confirm its clinical utility. Impact <UnorderedList Mark="Bullet"> <ItemContent> Our study establishes a significant link between platelet-to-high-density lipoprotein cholesterol ratio (PHR) and blood eosinophil counts (BEOC) in pediatric asthma, highlighting PHR as a potential biomarker for eosinophilic asthma phenotypes and expanding the understanding of disease mechanisms in this population. </ItemContent> <ItemContent> By identifying PHR as an integrated indicator of platelet activation, lipid metabolism, and type 2 immunity, our research bridges gaps in current knowledge and offers new insights for targeted asthma management. </ItemContent> <ItemContent> These findings have the potential to enhance clinical prediction and management of pediatric asthma by introducing PHR as a novel marker, though further validation is required to solidify its role in routine practice. </ItemContent> </UnorderedList>

Pediatric asthma: positive correlation between platelet-to-HDL-C ratio and blood eosinophil counts

期刊论文
发表日期：

2026年4月24日

查看全文

Jingjing Li,
Fei Luo,
Lumin Chen,
Meichai Lin

摘要

Background

Current evidence on the association between the platelet-to-high-density lipoprotein cholesterol ratio (PHR) and blood eosinophil counts (BEOC) is limited in pediatric asthma patients. This study aimed to assess the relationship between PHR and BEOC in this population.

Methods

Using data from the National Health and Nutrition Examination Survey (NHANES) from 2009 to 2020, we conducted a cross-sectional study of 2178 eligible participants. Multivariable linear regression (continuous and quartile PHR) analyzed the association, adjusted for key covariates. Dose-response was assessed using restricted cubic splines (RCS), and robustness was tested with stratified and sensitivity analyses.

Results

Among 2178 participants (mean age 12.6 ± 3.9 years; 56.3% male), multivariable linear regression revealed a significant positive correlation between PHR and BEOC (β = 12.34; 95% CI: 6.53 to 18.15; P < 0.001). RCS analysis indicated a linear relationship (P = 0.905 for nonlinearity). Subgroup analyses were stable across most strata, stronger in females. Sensitivity analyses in the stricter asthma cohort confirmed robustness.

Conclusions

This study reveals a significant, positive association between PHR and BEOC in pediatric asthma patients. PHR may serve as a potential biomarker for pediatric eosinophilic asthma phenotypes, though further prospective studies are needed to confirm its clinical utility.

Impact

Our study establishes a significant link between platelet-to-high-density lipoprotein cholesterol ratio (PHR) and blood eosinophil counts (BEOC) in pediatric asthma, highlighting PHR as a potential biomarker for eosinophilic asthma phenotypes and expanding the understanding of disease mechanisms in this population.

By identifying PHR as an integrated indicator of platelet activation, lipid metabolism, and type 2 immunity, our research bridges gaps in current knowledge and offers new insights for targeted asthma management.

These findings have the potential to enhance clinical prediction and management of pediatric asthma by introducing PHR as a novel marker, though further validation is required to solidify its role in routine practice.